Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions
Journal of Medicinal Chemistry · 11.05.2023 · 66 (9) · 6037-6046
DOI: 10.1021/acs.jmedchem.2c01692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.04.2023. Verfasst von Marina Miñarro-Lleonar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Univer…. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Econom??a y Competitividad, Generalitat de Catalunya.
Abstract (Originalsprache)
Targeted protein degradation is a promising therapeutic strategy, spearheaded by the anti-myeloma drugs lenalidomide and pomalidomide. These drugs stabilize very efficiently the complex between the E3 ligase Cereblon (CRBN) and several non-native client proteins (neo-substrates), including the transcription factors Ikaros and Aiolos and the enzyme Caseine Kinase 1α (CK1α,), resulting in their degradation. Although the structures for these complexes have been determined, there are no evident interactions that can account for the high efficiency of formation of the ternary complex. We show that lenalidomide's stabilization of the CRBN-CK1α complex is largely due to hydrophobic shielding of intermolecular hydrogen bonds. We also find a quantitative relationship between hydrogen bond robustness and binding affinities of the ternary complexes. These results pave the way to further understand cooperativity effects in drug-induced protein-protein complexes and could help in the design of improved molecular glues and more efficient protein degraders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Unitat de Fisicoquímica, Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Av. Joan XXIII, 27-31, 08028 Barcelona, Spain.
- Institut de Química Teòrica i Computacional (IQTC), Facultat de Química i Física, Universitat de Barcelona (UB), C. Martí i Franquès, 1, 08028 Barcelona, Spain.
- Institut de Biomedicina, Facultat de Biologia, Universitat de Barcelona (UB), Av. Diagonal, 643, 08028 Barcelona, Spain.
- Catalan Institution for Research and Advanced Studies (ICREA), Pg. Lluís Companys, 23 08010 Barcelona, Spain.
ORCID-Profile: Marina Miñarro-Lleonar, Andrea Bertran-Mostazo, Xavier Barril, Jordi Juárez-Jiménez
Förderung
- Ministerio de Econom??a y Competitividad
- Generalitat de Catalunya
Zitieren
APA
Miñarro-Lleonar, M., Bertran-Mostazo, A., Duro, J., Barril, X., & Juárez-Jiménez, J. (2023). Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions. Journal of Medicinal Chemistry, 66(9), 6037-6046. https://doi.org/10.1021/acs.jmedchem.2c01692
Vancouver
Miñarro-Lleonar M, Bertran-Mostazo A, Duro J, Barril X, Juárez-Jiménez J. Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions. Journal of Medicinal Chemistry. 2023;66(9):6037-6046. doi:10.1021/acs.jmedchem.2c01692
BibTeX
@article{MiarroLleonar2023,
author = {Miñarro-Lleonar, Marina and Bertran-Mostazo, Andrea and Duro, Jorge and Barril, Xavier and Juárez-Jiménez, Jordi},
title = {Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {9},
pages = {6037--6046},
doi = {10.1021/acs.jmedchem.2c01692}
}
EUVIMED